Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Arginase 1/ARG1/liver Arginase Antibody (ARG1/1125) - IHC-Prediluted, Novus Biologicals™

Mouse Monoclonal Antibody
Supplier: Novus Biologicals NBP248229
Description
Arginase 1/ARG1/liver Arginase Monoclonal specifically detects Arginase 1/ARG1/liver Arginase in Human samples. It is validated for Immunohistochemistry, Immunohistochemistry-Paraffin.Specifications
Arginase 1/ARG1/liver Arginase | |
Monoclonal | |
Unconjugated | |
10mM PBS and 0.05% BSA with 0.05% Sodium Azide | |
ARG1 | |
Recombinant human Arginase 1/ARG1/liver Arginase protein fragment (around aa11-97) (exact sequence is proprietary) (Uniprot: P05089) | |
Protein A or G purified | |
RUO | |
Primary | |
Recognizes a protein of 35-38kDa, which is identified as Arginase 1 (ARG1). Arginase is a manganese metallo-enzyme that catalyzes the hydrolysis of arginine to generate ornithine and urea. Arginase I and II are isoenzymes which differ in subcellular localization, regulation, and possibly function. Arginase I is a cytosolic enzyme, which is expressed mainly in the liver as part of the urea cycle, whereas arginase II is a mitochondrial protein found in a variety of tissues. Antibody to ARG-1 labels hepatocytes in normal tissues and granulocytes in peripheral blood. ARG-1 is a sensitive and specific marker for identification of hepatocellular carcinoma. | |
Store at 4C. | |
IgG3 κ |
Immunohistochemistry (Paraffin) | |
ARG1/1125 | |
Immunohistochemistry-Paraffin | |
arginase 1, arginase, liver, arginase-1, EC 3.5.3.1, Liver-type arginase, Type I arginase | |
Mouse | |
36.5 kDa | |
7 mL | |
Cancer, Cellular Markers, Chromatin Research, Lipid and Metabolism, Myeloid derived Suppressor Cell | |
383 | |
Human | |
Purified |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction